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Abstract 
Background: The objective of this study is to systematically review the literature on economic 
evaluations of interventions for the early diagnosis of Alzheimer's disease (AD) and related 
disorders and to describe their general and methodological characteristics. We focused on the 
diagnostic aspects of the decision models to assess the applicability of existing decision models for 
the evaluation of the recently revised diagnostic research criteria for AD. 
Methods: PubMed and the National Institute for Health Research Economic Evaluation database 
were searched for English-language publications related to economic evaluations on diagnostic 
technologies. Trial-based economic evaluations were assessed using the Consensus on Health 
Economic Criteria list. Modeling studies were assessed using the framework for quality assessment 
of decision-analytic models. 
Results: The search retrieved 2109 items, from which eight decision-analytic modeling studies and 
one trial-based economic evaluation met all eligibility criteria. 
Conclusions: Diversity among the study objective and characteristics was considerable and, despite 
considerable methodological quality, several flaws were indicated. Recommendations were 
focused on diagnostic aspects and the applicability of existing models for the evaluation of recently 
revised diagnostic research criteria for AD. 
 
  
INTRODUCTION 
Alzheimer's disease (AD) and other dementing disorders are common in the elderly, with a 
worldwide prevalence estimated in 2010 at 35.6 million, which will increase to 115.4 million in 
2050. AD has a substantial impact on the person who suffers from the disease, his or her family, 
and society [1] and [2]. The total worldwide cost of AD and other dementing disorders was 
estimated at $604 billion in 2010 [3]. 
Earlier diagnosis and early intervention are considered important mechanisms to manage the 
worldwide impact of the disease. Early diagnosis can be described as a “timely” recognition of mild 
dementia in response to a patient's complaints to ensure that disabled individuals receive the 
necessary support and care or as the “symptomatic predementia” diagnosis when cognition is 
impaired but functioning not yet affected (typically referred to as mild cognitive impairment) [4]. 
Until recently, the diagnosis of AD was largely based on clinical judgment using the NINCDS-ADRDA 
criteria [5]. These criteria were recently revised [6], [7] and [8] to enhance diagnostic accuracy and 
enable an early diagnosis even when only very mild clinical symptoms are present. Biomarkers in 
cerebrospinal fluid (CSF), positron emission tomography (PET), magnetic resonance imaging (MRI), 
and photon emission tomography (SPECT) are attributed a more prominent role in the new 
diagnostic research criteria. However, validation of these research criteria is needed before the role 
of new biomarkers can be adopted in clinical practice [9]. 
The ultimate goal of diagnostic testing is to guide disease management to improve patient 
outcomes and patient well-being. Tests that lack this potential are considered obsolete [10] and 
[11]. Furthermore, because health-care resources are scarce and must be allocated efficiently, 
decision-makers require evidence of the cost-effectiveness of diagnostic tests before adoption in 
clinical practice. Such evidence can be generated by decision-analytic models which are defined as 
a set of mathematical relationships that form a structure reflecting the natural progression of a 
disease. By simulating patient cohorts, these models enable the estimation of the likelihood of each 
consequence and its corresponding costs and effects [12] and [13]. Trial-based economic 
evaluations, in which costs and health-care outcomes are measured during clinical trials, can also 
provide evidence of cost-effectiveness. 
Decision-analytic models of AD have been reviewed extensively by Cohen et al [14]. However, this 
review only included models that project disease progression, excluding possible relevant evidence 
on the evaluation of diagnostic techniques. Furthermore, the applicability of existing decision 
models to evaluate the recently revised research criteria has not been elaborated. This raises the 
urgent need for a review of economic evaluations of diagnostic interventions for AD. 
The objective of this study was to systematically review the literature on economic evaluations of 
interventions for the early diagnosis of AD and related disorders and to describe their general and 
methodological characteristics. Using these results, recommendations for future studies were 
focused on the diagnostic aspects of the decision models to assess the applicability of existing 
decision models for the evaluation of the recently revised diagnostic research criteria for AD. 
 
METHODS 
Search strategy 
A systematic literature review was performed to identify economic evaluations of diagnostic 
interventions for AD or related dementias. The following eligibility criteria were applied: 
 
1. The study should focus on a population, either an empirical (primary data) or a theoretical 
(model), which is suffering from or suspected of suffering from AD or related disorders 
(vascular dementia, dementia with Lewy bodies, and frontotemporal dementia). The 
population should consist of previously undiagnosed individuals. Studies of 
neurodegenerative disorders were excluded (e.g., Parkinson's, Huntington's disease, or 
depression). 
2. The population reflects humans, 55 years of age or older. 
3. The intervention is a diagnostic technology, tool, questionnaire, process, procedure, or 
protocol used for a timely or symptomatic predementia diagnosis of AD or related 
dementias in a clinical setting. Screening tools and risk, severity, or progression analyses 
were excluded (screening tools such as the Mini-Mental State Examination [MMSE] or DNA 
risk assessment). 
4. The study reports primary patient and/or cost data or uses a mathematical model that is 
based on such data. Reviews, case studies, and publications that merely describe 
methodological issues were excluded. 
5. The study is an economic evaluation: either a cost-consequence [15] analysis or a full 
economic evaluation (cost-effectiveness, cost-utility, or cost-benefit analyses). Partial 
economic evaluations, which do not include a comparison between different strategies or 
do not analyze both costs and consequences [16], were excluded. 
 
PubMed and the National Institute for Health Research Economic Evaluation Database databases 
[17] and [18] were searched through March 2011. Medical subject headings and free text words on 
dementia, diagnosis, and economic evaluation were used to identify relevant English-language 
articles with an available abstract (see Appendix 1 for the full search query). 
Two reviewers (R.H. and C.W.) independently assessed titles. A title was excluded if both reviewers 
agreed that it explicitly met one of the exclusion criteria. The same reviewers independently 
assessed abstracts of the remaining titles. An abstract was excluded if either reviewer considered 
that it did not meet all five inclusion and exclusion criteria. Dissimilarities in the reviewers' 
assessments were resolved by discussion. The full article was assessed if the remaining abstracts 
had dissimilarities that could not be otherwise resolved. If an article was not accessible, the author 
was contacted to request a copy of the original publication. A third reviewer (J.S.) resolved the 
remaining differences in the reviewer's assessments; this third reviewer made the final decision as 
to whether the article would be included. See Appendix 2 for an overview of the study selection 
process. 
 
Analyses 
General study characteristics of all of the included articles are described in Table 1. For modeling 
studies, the model type was scored separately for the diagnostic and treatment part of the model. 
A Markov model is characterized by mutually exclusive disease states that represent the possible 
consequences of the options under evaluation. Disease progression is reflected by the transition of 
a patient's disease states over discrete time periods [12]. We used the term “state-independent” 
for mathematical models that apply a fixed time cycle similar to a Markov model but reflect the 
disease progression on a continuous scale and not by mutually exclusive disease states, such as the 
MMSE categories mild AD (MMSE 21–26), moderate AD (MMSE 14–20), moderately severe AD 
(MMSE 10–14), and severe AD (MMSE <10). If the treatment was only summarized in one or more 
fixed outcome values and was not represented by a mathematical model, it was scored as “static”. 
Buxton et al [19] described five different roles of modeling in an economic evaluation that we used 
to classify all of the modeling studies: extrapolating beyond data observed in trial, linking the 
intermediate (clinical) endpoints to final outcomes, generalizing to other settings, synthesizing 
head-to-head comparisons where relevant trials do not exist, and informing decisions in the 
absence of hard data. 
Methodological characteristics of the trial-based economic evaluations were assessed using the 
Consensus on Health Economic Criteria (CHEC) list [20] (see Table 2). Methodological characteristics 
of the modeling studies were assessed using the framework for quality assessment of decision-
analytic models [21] and [22] (see Table 3), which includes three key themes: structure, data, and 
consistency. Questions S3.2, S3.3, and S8 required expert knowledge in the field of AD and were 
clarified by a psychiatrist (F.V.). Furthermore, the framework is most likely intended for treatment 
interventions, although diagnostic interventions are the focus of this review and required 
adjustment of the items D2b1 and D2b2 that are described in Table 3. Two reviewers (C.W. and 
R.H.) independently performed analyses. In one case, one of the reviewers was the author of the 
paper being assessed; therefore, this reviewer was replaced by another reviewer (P.A.) to ensure 
objectivity. Dissimilarities in scoring were resolved by discussion. If discussion was not successful, a 
third reviewer (J.S.) determined the final score. Both of the checklist questions were answered with 
“yes” if both reviewers agreed that the study paid sufficient attention to an item, “no” if the item 
was not fulfilled or if insufficient information was available to assess the item, or “N/A” (not 
applicable) if the question was either not applicable to the study or if it referred to a previous 
question scored as “no”. A summary score for each article was not applied because this quantitative 
scoring system was not considered to be sufficiently reliable and valid as a means of quality 
assessment. Therefore, a qualitative summary is provided to better distinguish major from minor 
methodologic flaws. 
 
RESULTS 
The search retrieved 2109 titles, of which 90 did not have an abstract available, 84 were duplicates, 
and an additional 180 were not in English. From the remaining 1755 titles, 936 were excluded based 
on the exclusion criteria. Of the remaining 819 titles, 735 were excluded after reading the abstracts, 
leaving 84 articles for assessment by R.H. and C.W. After reading the full articles, they excluded 75 
articles on the basis of the exclusion criteria, of which 2 were assessed by the third reviewer (J.S.) 
because a decision could not be made through discussion between R.H. and C.W. Thus, a total of 
nine studies [23], [24], [25], [26], [27], [28], [29], [30] and [31] were included in the review. Fig. 1 
displays a flowchart of the inclusion and exclusion process. Three articles [24], [25] and [26] 
analyzed a combination of two models of which the treatment part was published in a different 
article [32] and [33]. To fully evaluate the model, this publication was also included for assessment. 
Furthermore, the economic evaluation in two articles [25] and [26] was based on the same model 
and a similar situation applies to references 27 and 28. If the articles referred to one another the 
information from the referenced article was also used to assess the article for this review. 
 
Figure 1: Flowchart of the inclusion process of the search results. 
 
 
Table 1 provides an overview of the study characteristics. The studies can be divided into two 
categories on the basis of their objective. The first consists of three studies evaluating early 
diagnoses, which are strategies aimed at preventing underdiagnosis (i.e., timely recognition of 
patients suffering from dementia) to bring forward treatment. Although gained treatment effects 
in patients who would otherwise be undiagnosed were evaluated, the impact of an incorrect 
diagnosis (i.e., a false positive or false negative test outcome) was not included [23], [24] and [30]. 
The second category consists of six studies evaluating a specific diagnostic test or imaging strategy. 
Except for the trial-based study, a disease progression model was applied to describe costs and 
effects of true- and false-positive and -negative diagnostic pathways [25], [26], [27], [28], [29] and 
[31]. 
Diversity among the study characteristics was considerable on several items. Strategies under 
evaluation varied from specific imaging techniques to multidisciplinary assessments. Population 
ranged from non-demented patients with early symptoms to moderate dementia evaluated in 
Literature search  
PubMed and NHS EED with free 
text words and MeSH headings 
Search results (n=2109) 
Titles assessed (n=1755) 
Excluded based on criteria (n=936) 
1) Patient already diagnosed or other disease type (658),  
2) Non-human or aged <55 (48),  
3) Screening or risk/severity/progression analyses (191),  
4) Review, case study or methodological issue (39).  
Abstracts assessed (n=819) 
Excluded based on criteria (n=735) 
1) Not suspected of or suffering from Alzheimer’s disease or related 
dementias (139),  
2) Different from target population (20),  
3) No diagnostic intervention (394),  
4) No primary data (142),  
5) No economic evaluation (40).  
 
Full articles assessed (n=84) 
Included for review (n=9) 
Excluded based on criteria (n=75) 
1) Not suspected of or suffering from Alzheimer’s disease or related 
dementias (4),  
2) Different from target population (1),  
3) No diagnostic intervention (31)  
4) No primary data (5),  
5) No economic evaluation (34) 
Excluded (n=354) 
Duplicates (84) 
Non-English (180) 
No abstract (90) 
 
various care settings. The time horizon ranged from 1 year to lifetime. At last, study outcomes and 
conclusions on the adoption of the intervention under evaluation in clinical practice differed 
between the studies. 
  
Table 1: General study characteristics 
Author Banerjee et al. [23] Getsios et al.[24]* McMahon et al.[25]† McMahon et al.[26]† 
Publication year 2009 2012 2000 2003 
Country UK UK US US 
Objective Analyze the costs and 
benefits of commissioning 
memory services for early 
diagnosis and 
intervention for dementia 
Evaluate the cost-
effectiveness of early 
assessment and 
treatment with AD with 
Donepezil 
Evaluate the cost-
effectiveness of 
functional neuroimaging  
Evaluate the cost-
effectiveness of PET in the 
diagnosis of AD 
Study type 
 
Modeling Modeling Modeling Modeling 
Diagnostic model‡ Static discrete event simulation Decision-tree Decision-tree (based upon 
model McMahon et.al.) 
Treatment model‡ 
 
Mathematical model discrete event simulation Markov model Markov model 
Role of modeling§ Informing decisions in the 
absence of hard data 
Informing decisions in the 
absence of hard data 
Synthesizing head-to-
head comparisons where 
relevant trials do not exist  
Synthesizing head-to-
head comparisons where 
relevant trials do not exist 
Base case situation 
 
 
 
Current practice Early assessment for AD 
and treatment with 
Donepezil 
Standard examination Standard examination 
Comparative strategies¶ A multi-disciplinary and 
interagency team to 
generate early diagnosis 
(1) Treatment without 
early assessment; (2) No 
early assessment and no 
treatment 
(1) MRI plus DSC MRI; (2) 
Visual SPECT; (3) 
Computed SPECT (all 
added to standard 
examination) 
(1) DSC MRI; (2) FDG PET; 
(3) Computed SPECT (all 
added to standard 
examination) 
Impact of diagnostic test 
included in the model 
Bring forward treatment 
(incorrect diagnoses not 
modeled) 
Bring forward treatment 
(incorrect diagnoses not 
modeled) 
A disease progression 
model is applied on true 
and false positive and 
negative diagnoses 
A disease progression 
model is applied on true 
and false positive and 
negative diagnoses 
Diagnostic care setting 
 
 
 
Existing primary and 
secondary care services in 
England 
GP and specialist centers 
in UK 
A specialized Alzheimer 
disease center (tertiary 
Alzheimer disease clinic) 
A specialized Alzheimer 
disease center 
Study population Patients in an early state 
of dementia 
Patients with 
undiagnosed AD 
Patients with mild or 
moderate dementia (at 
presentation to an 
Alzheimer disease center) 
patients with mild or 
moderate dementia who 
present to specialized AD 
centers 
Primary patient level data 
 
 
N/A N/A N/A N/A 
Perspective Societal Health care payer and 
societal 
Societal  Societal 
Time horizon 10 years 10 years 18 months 18 months 
Outcome  measure 
 
Net benefit ICER ICER ICER 
Main results NPV over 10 years: -£950 
million. A gain of between 
0.01 and 0.02 QALYs per 
person year would render 
the service cost-effective 
Early assessment and 
treatment dominates 
both other options under 
evaluation 
ICER DSC MRI: 
$479,500/QALY compared 
with the usual diagnostic 
work-up. Visual or 
quantitative SPECT was 
dominated 
FDG PET and sPECT were 
dominated. ICER DSC 
MRI: $598,800/QALY 
compared to standard 
examination.  
Conclusion This presents for debate 
support for developing 
nationwide services for 
early identification and 
treatment of dementia 
The analysis suggest 
substantial benefits in 
terms of both patient and 
economic outcomes for 
early assessment and 
early treatment of AD 
Adding functional 
neuroimaging to usual 
diagnostic regimen is not 
cost-effective given the 
effectiveness of currently 
available therapies 
PET may have high 
diagnostic accuracy, but 
adding it to the standard 
diagnostic regimen at AD 
clinics would yield limited, 
if any, benefits at very 
high costs 
Abbreviations: AD, Alzheimer's disease; CT, computerized tomography; DSC, dynamic susceptibility-weighted contrast-
enhanced; FDG, fluorodeoxyglucose; ICER, incremental cost-effectiveness ratio; MRI, magnetic resonance imaging;  
N/A, not applicable; NICE, National Institute for Health and Clinical Excellence; NPV, net present value; NS, not stated; 
PET, positron emission tomography; QALE, quality adjusted life expectancy; QALY, quality adjusted life year; SPECT, 
single photon emission computed tomography; UK, United Kingdom; US, United States; AU, Australia; 
 
  
Table 1: continued 
Moulin-Romsee et al.[27] Silverman et al.[28] Simon et al.[29] Weimer et al.[30] Wolfs et al.[31] 
2005 2002 1985 2009 2009 
Belgium  US US US NL 
Estimate the economic 
effects of incorporating 
FDG PET in the diagnostic 
work-up of AD 
Compare the relative 
value of a conventional 
and proposed approach 
using PET to assess early 
AD  
Estimating the health 
benefits and economic 
costs of using alternative 
scanning strategies for 
diagnosing dementia 
Evaluates the costs and 
benefits of the early 
identification and 
treatment of AD patients 
Evaluate the cost-
effectiveness of 
integrated 
multidisciplinary 
diagnostic facility for 
dementia 
Modeling Modeling Modeling Modeling Trial-based economic 
evaluation 
Decision-tree (based upon 
model Silverman et al.) 
Decision-tree Decision-tree Static N/A 
Static Static Static state independent 
mathematical model 
N/A 
Synthesizing head-to-
head comparisons where 
relevant trials do not exist  
Synthesizing head-to-
head comparisons where 
relevant trials do not exist  
Synthesizing head-to-
head comparisons where 
relevant trials do not exist 
Informing decisions in the 
absence of hard data 
N/A 
Routine practice for the 
diagnosis of AD 
Current practice for 
expert evaluation of 
dementia  
CT scanning when 
historical or physical 
findings suggest a 
treatable illness (S-CT) 
Later diagnosis and drug 
treatment 
Diagnosis made by GP or 
existing regional services 
FDG PET incorporated in 
routine practice 
FDG PET after ruling out 
other conditions  
(1) Routine evaluation 
with CT scanning (R-CT); 
(2) Routine MRI to 
replace routine CT (R-
MRI) 
Immediate diagnosis and 
intervention 
Multidisciplinary 
assessment combining 
hospital setting and 
community mental health 
setting 
A summary effect of 
overtreatment and under 
treatment is on false 
diagnoses  
A summary effect of 
overtreatment and under 
treatment is on false 
diagnoses 
(quality adjusted) life 
expectancy of patients 
with under-diagnosed 
treatable conditions 
Bring forward treatment 
(incorrect diagnoses not 
modeled) 
N/A 
NS Current practice 
standards for expert 
evaluation of dementia 
NS NS GP or home visit and 
Geriatric Medicine and 
Geriatric Psychiatry 
hospital departments 
NS 
 
 
 
geriatric patients with 
early symptoms of 
cognitive decline 
individuals aged 60, 70, or 
80 and presenting with a 
dementing illness  
AD patients suffering 
from cognitive decline 
patients suspected of 
having  dementia or a 
cognitive disorder (age 
55+) 
N/A N/A N/A N/A Quality of life and 
resource consumption 
data on 219 patients 
NS 
 
Health care payer NS Societal Societal 
NS 12 months Lifetime Lifetime  12 months 
Cost savings per accurate 
diagnosis 
Costs per accurate 
diagnoses 
ICER Net benefit ICER 
Cost-savings per accurate 
diagnosis ranged from 
623–6110 Euro in favor of 
the proposed algorithm 
with PET 
Costs per correct 
diagnosis by the 
conventional algorithm: 
$5,185 and proposed 
algorithm: $4,047 
Cost per additional year 
of QALE from S-CT to R-CT 
is below $50,000. 
Comparing R-MRI to R-CT 
incremental cost ranges 
from $46,000 to $144,000 
Early identification and 
treatment potentially 
result in large, positive 
net social benefits as well 
as positive net savings  
ICER: €1267/QALY. This 
estimate is within an 
acceptable range of 
uncertainty 
Incorporating FDG PET in 
the clinical work up can 
result in substantial 
benefit in terms of health-
care cost savings and 
benefit for the patient. 
 
Improved care can be 
economically achieved 
through incorporation of 
PET into the diagnostic 
work-up 
Given current treatment 
limitations in dementia it 
appears that MRI will 
have little immediate 
health impact on this 
problem 
Early diagnosis and 
treatment of AD are 
socially desirable in terms 
of increasing economic 
efficiency, and fiscally 
attractive 
Integrated 
multidisciplinary 
diagnostic facility is cost-
effective for the diagnosis 
and management of 
dementia in community 
patients 
* Part of the model was described in Getsios et.al. [32] 
† Part of the model was described in Neuman et.al. [33] 
‡ Model type was valued as "static" if not represented by a mathematical model (e.g., when the effect was summarized 
in one or more fixed outcome values) 
§ Model types were based on Buxton et.al. [19] 
¶ Additional strategies evaluated in a sensitivity analysis are not stated 
  
Table 2 displays the application of the CHEC list [20] on the trial-based economic evaluation. A time 
horizon of 1 year was considered too short for the inclusion of all relevant costs and consequences 
and generalizability was insufficiently addressed. 
 
Table 2: Scores on the CHEC list of trial-based economic evaluation studies 
CHEC-list Item Wolfs et 
al.[31] 
1. Is the study population clearly described?  Y 
2. Are competing alternatives clearly described?  Y 
3. Is a well-defined research question posed in answerable form?  Y 
4. Is the economic study design appropriate to the stated objective?  Y 
5. Is the chosen time horizon appropriate in order to include relevant costs and consequences?  N 
6. Is the actual perspective chosen appropriate?  Y 
7. Are all important and relevant costs for each alternative identified?  Y 
8. Are all costs measured appropriately in physical units?  Y 
9. Are costs valued appropriately?  Y 
10. Are all important and relevant outcomes for each alternative identified?  Y 
11. Are all outcomes measured appropriately?  Y 
12. Are outcomes valued appropriately?  Y 
13. Is an incremental analysis of costs and outcomes of alternatives performed?  Y 
14. Are all future costs and outcomes discounted appropriately?  Y 
15. Are all important variables, whose values are uncertain, appropriately subjected to sensitivity 
analysis?  
Y 
16. Do the conclusions follow from the data reported?  Y 
17. Does the study discuss the generalizability of the results to other settings and patient/client 
groups?  
N 
18. Does the article indicate that there is no potential conflict of interest of study researcher(s) and 
funder(s)?  
Y 
19. Are ethical and distributional issues discussed appropriately?  N 
Abbreviations: N, the item was not fulfilled or insufficient information was available in the article to assess the item; Y, 
both reviewers agreed that the study paid sufficient attention to an item 
 
Table 3 displays the results of the quality assessment using the framework for decision-analytic 
models [21]. Twenty framework items required scoring by the third reviewer (J.S.); two were due 
to dissimilarities between the two reviewers that could not be resolved by discussion. Items in 
several topics were not fulfilled or were insufficiently addressed by most included studies. The 
following four were also considered of importance regarding this review's focus on the diagnostic 
aspects of the decision models. Model scope was considered insufficiently addressed because a 
lifetime horizon was disregarded and the population and setting were mostly not addressed. The 
options under evaluation were considered not fulfilled because many studies did not evaluate all 
feasible options or did not justify their exclusion, especially regarding combinations of diagnostic 
tests. Further, several items of the data identification were not addressed sufficiently, especially 
regarding the identification of key parameters. Lastly, according to the checklist, all types of 
uncertainty analyses were considered not described or not performed by almost all included 
studies. 
 
  
Table 3: Scores on the framework for quality assessment of decision-analytic models 
Study number, author, 
source 
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Structure (S)           
S1: Statement of 
decision 
problem/objective 
1 Is there a clear statement of the decision 
problem? 
Y Y N Y Y Y Y Y 
 2 Is the objective of the evaluation and 
model specified and consistent with the 
stated decision problem? 
Y Y N/A Y Y Y Y Y 
  3 Is the primary decision maker specified? Y N N N N Y N Y 
S2: Statement of 
scope/perspective 
1 Is the perspective of the model stated 
clearly? 
Y Y Y Y N Y N Y 
 2 Are the model inputs consistent with the 
stated perspective? 
N Y Y Y N/A Y N/A Y 
  3* Has the scope of the model been stated 
and justified? 
N N N N N N N N 
  4 Are the outcomes of the model consistent 
with the perspective, scope and overall 
objective of the model? 
N/A N/A N/A N/A N/A N/A N/A N/A 
S3: Rationale for 
structure 
1 Has the evidence regarding the model 
structure been described? 
N Y Y Y Y Y N Y 
  2† Is the structure of the model consistent 
with a coherent theory of the health 
condition under evaluation? 
N Y Y Y Y Y Y Y 
  3‡ Have any competing theories regarding 
model structure been considered? 
N N N N N N N N 
 4 Are the sources of data used to develop 
the structure of the model specified? 
N Y Y Y Y Y N Y 
  5 Are the causal relationships described by 
the model structure justified 
appropriately? 
Y Y Y Y Y Y Y Y 
S4: Structural 
assumptions 
1 Are the structural assumptions 
transparent and justified? 
Y Y Y Y Y Y Y Y 
 2 Are the structural assumptions reasonable 
given the overall objective, perspective 
and scope of the model? 
N/A N/A N/A N/A N/A N/A N/A N/A 
S5: 
Strategies/comparator
s 
1 Is there a clear definition of the options 
under evaluation? 
N Y Y Y Y Y Y N 
  2 Have all feasible and practical options 
been evaluated? 
N N Y Y N N N Y 
  3 Is there justification for the exclusion of 
feasible options? 
N N Y Y N N N N/A 
S6: Model type 1 Is the chosen model type appropriate 
given the decision problem and specified 
causal relationships within the model? 
N Y Y Y Y Y Y N 
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S7: Time horizon 1 Is the time horizon of the model sufficient 
to reflect all important differences 
between options? 
Y Y Y Y N Y Y Y 
  2 Is the time horizon of the model, and the 
duration of treatment and treatment 
effect described and justified? 
N Y Y Y N/A Y Y N 
 3 Has a lifetime horizon been used? N N N N N N Y Y 
 4 If not, has a shorter time horizon been 
justified? 
N N Y Y N N N/A N/A 
S8: Disease 
states/pathways 
1§ Do the disease states (state transition 
model) or the pathways (decision tree 
model) reflect the underlying biological 
process of the disease in question and the 
impact of interventions? 
N Y Y Y Y Y Y N 
S9: Cycle length 1 Is the cycle length defined and justified in 
terms of the natural history of disease? 
N/A N/A Y** Y** N/A N/A N/A Y 
Data (D)           
D1: Data identification 1 Are the data identification methods 
transparent and appropriate given the 
objectives of the model? 
N Y** N N Y Y N N 
  2 Where choices have been made between 
data sources, are these justified 
appropriately? 
N Y** N Y Y Y N N 
  3 Has particular attention been paid to 
identifying data for the important 
parameters in the model? 
N Y Y Y Y Y Y Y 
 4 Has the process of selecting key 
parameters been justified and systematic 
methods used to identify the most 
appropriate data? 
N/A N N N N N N N 
 5 Has the quality of the data been assessed 
appropriately? 
N Y** N N Y Y N N 
 6 Where expert opinion has been used, are 
the methods described and justified? 
N/A N/A Y Y N/A N/A N N/A 
D2: Pre-model data 
analysis 
1 Are the pre-model data analysis 
methodology based on justifiable 
statistical and epidemiological 
techniques? 
N/A Y** Y** Y** N/A N/A N/A Y 
D2a: baseline data 1 Is the choice of baseline data described 
and justified? 
N Y** Y Y Y Y Y Y 
 2 Are transition probabilities calculated 
appropriately? 
N/A N/A Y** Y** Y Y Y Y 
 3 Has a half cycle correction been applied to 
both cost and outcome? 
N/A N/A N** N** N/A N/A N/A N/A 
 4 If not, has this omission been justified? N/A N/A N** N** N/A N/A N/A N/A 
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D2b: treatment effects 
and diagnostic 
accuracy 
1¶ If relative diagnostic accuracy have been 
derived from trial data, have they been 
synthesised using appropriate techniques? 
N/A N/A Y Y Y Y Y N/A 
 2# Have the methods and assumptions used 
to extrapolate diagnostic accuracy to final 
outcomes been documented and 
justified? 
N/A N/A Y Y Y Y Y N/A 
 3 Have alternative assumptions been 
explored through sensitivity analysis? 
N/A Y Y Y Y Y N N/A 
 4 Have assumptions regarding the 
continuing effect of treatment once 
treatment is complete been documented 
and justified? 
N/A Y N/A N/A N/A N/A N/A N/A 
 5 Have alternative assumptions been 
explored through sensitivity analysis? 
N/A Y N/A N/A N/A N/A N/A N/A 
D2c: quality-of-life 
weights (utilities) 
1 Are the utilities incorporated into the 
model appropriate? 
N/A Y Y Y N/A N/A Y Y 
 2 Is the source for the utility weights 
referenced? 
N/A Y Y Y N/A N/A N Y 
 3 Are the methods of derivation for the 
utility weights justified? 
N/A Y Y Y N/A N/A N N/A 
D3: Data incorporation 1 Have all data incorporated into the model 
been described and referenced in 
sufficient detail? 
Y Y Y Y N Y Y Y 
 2 Has the use of mutually inconsistent data 
been justified (i.e. are assumptions and 
choices appropriate)? 
N/A N/A N/A N/A N/A N/A N/A N/A 
 3 Is the process of data incorporation 
transparent? 
Y Y Y Y Y Y Y Y 
 4 If data have been incorporated as 
distributions, has the choice of 
distribution for each parameter been 
described and justified? 
N/A Y** N/A N/A N/A N/A N/A Y 
 5 If data have been incorporated as 
distributions, is it clear that second order 
uncertainty is reflected? 
N/A Y N/A N/A N/A N/A N/A N 
D4: Assessment of 
uncertainty 
1 Have the four principal types of 
uncertainty been addressed? 
N N N N N N N N 
 2 If not, has the omission of particular forms 
of uncertainty been justified? 
N N N N N N N N 
D4a: methodological 1 have methodological uncertainties been 
addressed by running alternative versions 
of the model with different 
methodological assumptions? 
N N N N N N N N 
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D4b: structural 1 is there evidence that structural 
uncertainties have been addressed via 
sensitivity analysis? 
N N N Y N Y N Y 
D4c: heterogeneity 1 has heterogeneity been dealt with by 
running the model separately for different 
subgroups? 
N N N N N N Y Y 
D4d: parameter 1 are the methods of assessment of 
parameter uncertainty appropriate? 
N Y N N N N N Y 
 2 has probabilistic sensitivity analysis been 
done, if not, has this been justified? 
N Y N N N N N N 
 3 If data are incorporated as point 
estimates, are the ranges used for 
sensitivity analysis stated clearly and 
justified? 
N N/A Y Y Y Y Y N/A 
Consistency (C)           
C1: Internal 
consistency 
1 Is there evidence that the mathematical 
logic of the model has been tested 
thoroughly before use? 
N N N N N N N N 
C2: External 
consistency 
1 Are the conclusions valid given the data 
presented? 
Y Y Y Y Y Y Y Y 
 2 Are any counterintuitive results from the 
model explained and justified? 
N/A N/A N/A N/A N/A N/A N/A N/A 
 3 If the model has been calibrated against 
independent data, have any differences 
been explained and justified? 
N/A N/A N/A N/A N/A N/A N/A N/A 
 4 Have the results of the model been 
compared with those of previous models 
and any differences in results explained? 
N Y N Y N Y N N 
Abbreviations: N, item was not fulﬁlled or insufﬁcient information was available; N/A, not applicable to the study or 
referred to a previous question scored with “N”; Y, both reviewers agreed sufﬁcient attention was paid to an item. 
* According to the framework, the model scope should include the perspective, involved technologies, population, 
setting, and time horizon at the outset of the study. 
† This item required expert knowledge in the field of AD. The structure of a model was therefore considered consistent 
with a coherent theory of AD if it included the following basic elements in the diagnostic process: history taking, 
examination of cognition, and structural imaging [43, 44]. Additionally, if treatment was included, it had to reflect 
cognition and a progressive decline according to a clinical measurement scale [14, 45] (e.g., the Mini-Mental State 
Examination (MMSE) or Clinical Dementia Rating).  
‡ This item required expert knowledge in the field of AD. As stated in the introduction, new research criteria assigning 
to biomarkers a fundamental role in the diagnostic process have recently been developed. Applying these research 
criteria to the diagnostic process is considered a competing theory regarding model structure.  
§ This item required expert knowledge in the field of AD. The underlying biological process was considered appropriate 
if disease states or pathways reflected cognition. 
¶ This item was changed to derivation of diagnostic accuracy. 
# This item was changed to extrapolation of diagnostic accuracy, according to its relevance within the hierarchical model 
of diagnostic efficacy [46]. 
** Information to score the item was only retrieved from the additional publication that described part of the model 
DISCUSSION 
The objective of the present study was to systematically review the literature on economic 
evaluations of interventions for the early diagnosis of AD and related disorders and to describe their 
methodological characteristics. Eight decision-analytic modeling studies and one trial-based 
economic evaluation were retrieved. Study quality was assessed using the framework for decision-
analytic models [21] and the CHEC list [20], and overall the results reflect considerable 
methodological quality. However, population and diagnostic setting (scope), interventions under 
evaluation, selection and quality assessment of key diagnostic input parameters, and uncertainty 
analyses were not fulfilled or were insufficiently addressed by most included studies. Although the 
study conclusions were considered valid given the data presented, the diversity in study 
characteristics and methodology could have a major impact on the cost-effectiveness estimate and 
do not allow for a valid comparison of the cost-effectiveness outcomes.  
We discuss the applicability of the diagnostic part of existing decision models for the economic 
evaluation of the recently revised diagnostic research criteria for AD. Two aspects were considered 
of major importance as indicated by the framework for diagnostic test evaluation by Van den Bruel 
et al [11]. 
The first aspect regards diagnostic test accuracy, which is highly dependent on patient population 
characteristics, clinical setting and (patient selection by) results of previously performed tests [10]. 
Most studies left the above aspects insufficiently described (i.e.: the scope was minimally 
addressed). Because the newly developed research criteria are targeted on various disease severity 
in specialized centers, it is important to specify the corresponding targeted population and setting 
in decision analyses to enable their evaluation. Furthermore, most studies limited the diagnostic 
options under evaluation and minimally addressed sensitivity analyses to evaluate alternative 
diagnostic scenarios. Therefore, possible diagnostic strategies such as using biomarkers as add-on 
or triage were insufficiently evaluated. Furthermore, the newly developed research criteria divide 
the AD biomarkers into two categories (biomarkers of β-Amyloid deposition and of neuronal injury) 
and emphasized the importance of evaluating different combinations. This was insufficiently 
explored by the options under evaluation or by the sensitivity analyses. Questions on optimal 
decision-making when biomarker results contradict or when to stop testing were not answered. 
The second aspect refers to the impact on patient outcome. Most studies in this review included 
only the impact of pharmacological treatment, which, in our opinion, underexposes the possible 
nonmedical effects in symptomatic predementia patients. Because current treatment guidelines do 
not advise medication in this disease phase and nonpharmacological treatments are mainly aimed 
at dementia-related symptoms [34], it leaves the diagnostic test impact mainly to nonmedical 
aspects [35], such as anxiety, depression, psychological well-being, (financial) decision-making, and 
future care planning [4], [36] and [37]). 
 
Recommendations 
Following these findings, three recommendations for future decision models to enable the 
evaluation of the new diagnostic research criteria can be made. First, we advise to describe in detail 
the model scope, including the intended goal as timely diagnosis or symptomatic predementia 
diagnosis, the population and clinical setting characteristics regarding disease state at the moment 
of diagnosis, and what diagnostic tests already have been performed in the population. We advise 
to describe these items separately as targeted by the decision model and as applied in the retrieved 
(literature) evidence on key diagnostic parameters such as test sensitivity and specificity. 
Second, we advise to include a variety of possible test combinations as options under evaluation or 
to address these by structural sensitivity analyses (e.g., the study of McMahon et al [26]). At last, 
we recommend representing the diagnostic strategy by a decision tree, including probabilities for 
each test outcome and their corresponding non-medical consequences, followed by a Markov 
model or discrete event simulation describing long-term disease progression [38] (for example as 
applied by two of the included studies [25] and [26]). 
 
Limitations 
Both the CHEC-list for trial-based economic evaluations and the framework for quality assessment 
of decision-analytic models support the assessment of studies for a review. Judgments, however, 
remain subjective and therefore the use of three reviewers was adopted for this evaluation. We 
recommend that such a procedure be used for future studies. Also, several items in the framework 
for decision-analytic models were interpreted in different ways and therefore required resolution 
by a third reviewer (JS). 
Furthermore, items including harm of testing, willingness to undergo a test, consequences of (false) 
diagnosis, purpose of testing regarding screening, diagnosis and prognosis, and place in the clinical 
pathway regarding other tests that have been performed are important in diagnostic test 
evaluation. However, major flaws on these items were not differentiated to minor flaws by using 
the quality assessment checklists. We applied a qualitative summary to enable such distinction 
though ideally a quantitative score would be applied that combines the different constructs of a 
model and assessed their relative importance to rate the quality of the studies. 
Non-medical consequences of testing in the absence of direct clinical benefits are considered 
important. Quality of life scales are potentially useful though rarely capture all possible test effects 
and therefore specific instruments are advised to capture the nonmedical effects [35]. Retrieving 
quality of life estimates will be a challenge for future research. Meanwhile, willingness to pay 
estimates can, despite of challenges in obtaining reliable estimates, help to isolate the non-medical 
value [39]. Neumann et al [40] found that on average people are willing to pay about $450 for an 
AD test in absence of treatment and that a positive test result influences future planning in part of 
the subjects. If non-medical consequences could not be quantified they should be assessed 
qualitatively. 
By excluding screening or risk assessment instruments we have not elaborated on the applicability 
of current decision models for the evaluation of the recently revised criteria for the pre-
symptomatic pre-dementia phase. These criteria are however indicated as “strictly for research 
purposes only” and at this moment less relevant to evaluate for applicability in clinical practice. 
Overall, the reviewers found that insufficient information was available for the assessment of all 
items of the framework for decision-analytic models, thereby increasing uncertainty about the 
interpretation and generalizability of the results. However, the quantity of publishable information 
is restricted by journal word count limits. The space available to describe all relevant aspects in 
detail is limited, especially for economic evaluations of diagnostic interventions, which most likely 
include both a diagnostic intervention and treatment options. A practical solution currently is to 
include an extensive appendix, as demonstrated by the model of Getsios et al [32] and, in a different 
field, by Van Gestel et al [41]. 
Issues of implementation were not included in the assessment instruments, though they may be of 
importance in assessing economic evaluations of diagnostic interventions for AD [16]. MRI and PET 
scans (and the production of PET tracers), for example, are not available in all hospitals. As a result, 
additional logistic effort or the reorganization of services may be necessary. 
All included studies have been performed before the publication of the revised criteria and 
obviously therefore have not necessarily adopted the preferred model scope or methodology to 
compare a variety of test combinations. An example of an ongoing study adopting such scope and 
taking account the recommendations from this review is the LeARN study [42] 
(clinicaltrials.gov/ct2/show/NCT01450891) from which the results will be available in 2013. 
 
Conclusion 
A systematic review of economic evaluations of interventions for the early diagnosis of AD and 
related disorders was conducted with the aim of describing their general and methodological 
characteristics. The search retrieved eight decision-analytic modeling studies and one trial-based 
economic evaluation. The overall results reflect considerable methodological quality. However, 
diversity among the study objective and characteristics was considerable and the topics scope, 
options under evaluation, data identification and uncertainty analyses were not fulfilled or 
insufficiently addressed. To apply current decision models for the assessment of the recently 
revised diagnostic research criteria for AD we recommend to describe in detail the model scope, to 
include a variety of possible test combinations as options under evaluation, and to apply an explicit 
quality of life estimate to reflect the impact of non-medical aspects. 
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APPENDIX 1. SEARCH STRATEGY PUBMED UP TO MARCH 2011 
# Search term 
#46 Search #8 and #24 and #45 
#45 Search #27 or #44 
#44 Search #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 
or #42 or #43 
#43 Search pharmaco-economic∗[Title/Abstract] 
#42 Search pharmacoeconomic∗[Title/Abstract] 
#41 Search cost$identificat∗[Title/Abstract] 
#40 Search cost$comparison∗[Title/Abstract] 
#39 Search cost$consequence∗[Title/Abstract] 
#38 Search cost$minimi∗[Title/Abstract] 
#37 Search cost$utili∗[Title/Abstract] 
#36 Search cost$stud∗[Title/Abstract] 
#35 Search cost$analy∗[Title/Abstract] 
#34 Search cost$evaluation∗[Title/Abstract] 
#33 Search cost$benefit∗[Title/Abstract] 
#32 Search cost$effective∗[Title/Abstract] 
#31 Search costing[Title/Abstract] 
#30 Search costly[Title/Abstract] 
#29 Search costs[Title/Abstract] 
#28 Search cost[Title/Abstract] 
#27 Search #25 or #26 
#26 Search models, economic/ 
#25 Search cost and cost analysis/ 
#24 Search #12 or #23 
#23 Search #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 
#22 Search cognitively$impair∗[Title/Abstract] 
#21 Search memory$disorder[Title/Abstract] 
#20 Search MCI[Title/Abstract] 
#19 Search cognitive$impair∗[Title/Abstract] 
#18 Search cognitive$disorder[Title/Abstract] 
#17 Search psychogeriatr∗[Title/Abstract] 
#16 Search neurodegen∗[Title/Abstract] 
#15 Search cognitive$dysfunct∗[Title/Abstract] 
#14 Search dement∗[Title/Abstract] 
#13 Search alzheimer∗[Title/Abstract] 
#12 Search #9 or #10 or #11 
#11 Search neurodegenerative diseases/ 
#10 Search dementia/ 
#9 Search alzheimer's disease/ 
#8 Search #6 or #7 
#7 Search diagnos∗[Title/Abstract] 
#6 Search #1 or #2 or #3 or #4 or #5 
#5 Search discriminant analysis/ 
#4 Search predictive value of tests/ 
#3 Search diagnosis, differential/ 
#2 Search sensitivity and specificity/ 
#1 Search diagnosis/ 
 
  
APPENDIX 2. SEARCH STRATEGY NATIONAL INSTITUTE FOR HEALTH 
RESEARCH ECONOMIC EVALUATION DATABASE UP TO MARCH 2011 
# Search term 
#1 MeSH Diagnosis EXPLODE 1 
#2 MeSH Sensitivity and Specificity EXPLODE 1 2 3 4 5 6 7 
#3 MeSH Diagnosis, Differential EXPLODE 1 
#4 MeSH Predictive Value of Tests EXPLODE 1 2 3 
#5 MeSH Discriminant Analysis EXPLODE 1 2 3 
#6 Diagnos∗ 
#7 #1 or #2 or #3 or #4 or #5 or #6 
#8 MeSH Alzheimer Disease EXPLODE 1 2 3 
#9 MeSH Dementia EXPLODE 1 2 
#10 MeSH Neurodegenerative Diseases EXPLODE 1 
#11 Alzheimer∗ OR dement∗ OR cognitive$dysfunct∗ OR neurodegen∗ OR psychogeriatr∗ OR 
cognitive$disorder OR cognitive$impair∗ OR MCI OR memory$disorder OR cognitively$impair∗ 
#12 #8 or #9 or #10 or #11 
#13 #7 AND #12 
Abbreviation: MeSH, Medical Subject Headings. 
∗ the wildcard character 
 
 
